Table 2:
Baseline assumptions of diagnostic sensitivity and specificity of the Pap test adopted in cost-effectiveness analysis studies by manufacturer involvement and funding
| Manufacturer involvement and funding | Mean (standard deviation) | |||||
|---|---|---|---|---|---|---|
| Sensitivity, baseline | Specificity, baseline | Sensitivity, upper range | Specificity, upper range | Sensitivity, lower range | Specificity, lower range | |
| Author affiliated with manufacturer | ||||||
| Yes | 60 (6) | 94 (6) | 79 (2) | 99 | 44 (7) | 90 |
| No | 64 (14) | 95 (4) | 83 (15) | 97 (4) | 48 (15) | 84 (14) |
| Funding from manufacturer | ||||||
| Yes | 57 (8) | 95 (2) | 81 (12) | 98 (1) | 43 (9) | 85 (5) |
| No | 66 (13)* | 94 (5) | 83 (15) | 97 (4) | 49 (15) | 84 (15) |
| Conflict of interest related to manufacturer | ||||||
| Yes | 61 (10) | 95 (2) | 82 (13) | 98 (1) | 46 (15) | 81 (22) |
| No | 67 (13)† | 95 (3) | 85 (11) | 97 (3) | 49 (15) | 86 (9) |
| Not reported | 54 (13)† | 89 (10) | 72 (25) | 95 (9) | 46 (13) | 81 (10) |
| Author affiliation with or funding from manufacturer | ||||||
| Yes | 58 (7) | 95 (5) | 81 (11) | 98 (1) | 43 (8) | 85 (5) |
| No | 67 (14)‡ | 94 (4) | 84 (15) | 97 (4) | 49 (15) | 84 (15) |
| Author affiliation with, funding from or conflict of interest related to manufacturer | ||||||
| Yes | 60 (10) | 95 (5) | 82 (12) | 98 (1) | 46 (14) | 81 (21) |
| No | 70 (12)* | 95 (3) | 86 (11) | 97 (3) | 49 (15) | 87 (9) |
| Other (nonmanufacturer) funding reported | ||||||
| Yes | 67 (13) | 95 (3) | 85 (12) | 98 (2) | 46 (14) | 83 (17) |
| No | 60 (11)§ | 94 (5) | 80 (16) | 97 (5) | 51 (14) | 85 (7) |
*
p < 0.001.
†
p < 0.05.
‡
p < 0.001
§
p < 0.01.